Episode description
Episode description
In this podcast, Prof Paolo Ghia discusses the current treatment landscape of Chronic Lymphocytic Leukemia (CLL), providing a guide for clinicians faced with an ever-growing number of therapeutic alternatives.
Within targeted therapies, a special focus is dedicated to BTK inhibitors and their different characteristics, and to the long-term results of the ASCEND trial. The management of CLL is changing rapidly, and Prof Ghia's expertise can help hematologists to choose the right treatment for their patients, even in high-risk cases, such as the ones with TP53 mutation or del(17p).
The podcast is based on the paper: "Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results", by Ghia P et al., published on HemaSphere in 2022.
Host: Dr Enrica Orsini; Guest: Prof Paolo Ghia
To learn more about CLL and updated treatment recommendations, check out our comprehensive CLL Program on the EHA Campus.
Discover more of EHA's social media microlearning here.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe